Methods of using adipose tissue-derived cells in the treatment of cardiovascular conditions
View Patent ↗Adipose derived regenerative cells are used to treat patients, including patients with cardiovascular conditions, diseases or disorders. Methods of treating patients include processing adipose tissue to deliver a concentrated amount of regenerative cells, e.g., stem and/or progenitor cells, obtained from the adipose tissue to a patient. The methods may be practiced in a closed system so that the stem cells are not exposed to an external environment prior to being administered to a patient. Accordingly, in a preferred method, adipose derived regenerative cells are placed directly into a recipient along with such additives necessary to promote, engender or support a therapeutic cardiovascular benefit.
1. A method of improving cardiac ejection fraction in a subject, comprising:
identifying a subject in need of improved cardiac ejection fraction; and
providing to the subject a composition comprising a concentrated population of adipose-derived regenerative cells sufficient to improve cardiac ejection fraction in said subject, wherein said concentrated population of adipose-derived regenerative cells comprises adipose-derived stem cells and endothelial progenitor cells, and wherein said concentrated population of adipose-derived regenerative cells is obtained by acquiring an adipose tissue sample, separating away adipocytes and connective tissue, and washing and concentrating said adipose-derived regenerative cells.
2. The method of claim 1 , wherein the subject is human.
3. The method of claim 1 , wherein said concentrated population of adipose-derived regenerative cells comprises precursor cells.
4. The method of claim 1 , wherein said composition is provided to said subject in a bolus.
5. The method of claim 1 , wherein said composition is provided to said subject in multiple doses.
6. The method of claim 1 , wherein the composition is provided to said subject via at least one of an endomyocardial, epimyocardial, intraventricular, intracoronary, retrograde coronary sinus, intra-arterial, intra-pericardial, or intravenous administration route.
7. A method of improving cardiac perfusion in a subject, comprising:
identifying a subject with insufficient cardiac perfusion; and
providing to the subject a composition that comprises an amount of a concentrated population of adipose-derived regenerative cells sufficient to improve cardiac perfusion in said subject, wherein said concentrated population of adipose-derived regenerative cells comprises stem cells and endothelial progenitor cells, and wherein said concentrated population of adipose-derived regenerative cells is obtained by acquiring an adipose tissue sample, separating away adipocytes and connective tissue, and washing and concentrating said adipose-derived regenerative cells.
8. The method of claim 7 , wherein the subject is human.
9. The method of claim 7 , wherein said concentrated population of adipose-derived regenerative cells comprises precursor cells.
10. The method of claim 7 , wherein said composition is provided to said subject in a bolus.
11. The method of claim 7 , wherein said composition is provided to said subject in multiple doses.
12. The method of claim 7 , wherein the composition is provided to said subject via at least one of an endomyocardial, epimyocardial, intraventricular, intracoronary, retrograde coronary sinus, intra-arterial, intra-pericardial, or intravenous administration route.
13. A method for preventing the progression of cardiac remodeling in a subject, comprising:
identifying a subject at risk of cardiac remodeling; and
providing to the subject an amount of a composition comprising a concentrated population of adipose-derived regenerative cells is sufficient to prevent the progression of cardiac remodeling in said subject, wherein said concentrated population of adipose-derived regenerative cells comprises stem cells and endothelial progenitor cells, and wherein said concentrated population of adipose-derived regenerative cells is obtained by acquiring an adipose tissue sample, separating away adipocytes and connective tissue, and washing and concentrating said adipose-derived regenerative cells.
14. The method of claim 13 , wherein the subject is human.
15. The method of claim 13 , wherein said concentrated population of adipose-derived regenerative cells comprises precursor cells.
16. The method of claim 13 , wherein said composition is provided to said subject in a bolus.
17. The method of claim 13 , wherein said composition is provided to said subject in multiple doses.
18. The method of claim 13 , wherein the composition is provided to said subject via at least one of an endomyocardial, epimyocardial, intraventricular, intracoronary, retrograde coronary sinus, intra-arterial, intra-pericardial, or intravenous administration route.
19. The method of claim 1 , wherein said concentrated population of adipose-derived regenerative cells is isolated in a closed system.
20. The method of claim 7 , wherein said concentrated population of adipose-derived regenerative cells is isolated in a closed system.
21. The method of claim 13 , wherein said concentrated population of adipose-derived regenerative cells is isolated in a closed system.
22. The method of claim 1 , wherein said concentrated population of adipose-derived regenerative cells is not cultured.
23. The method of claim 7 , wherein said concentrated population of adipose-derived regenerative cells is not cultured.
24. The method of claim 13 , wherein said concentrated population of adipose-derived regenerative cells is not cultured.
25. The method of claim 19 , wherein said concentrated population of adipose-derived regenerative cells is not cultured.
26. The method of claim 20 , wherein said concentrated population of adipose-derived regenerative cells is not cultured.
27. The method of claim 21 , wherein said concentrated population of adipose-derived regenerative cells is not cultured.
28. The method of claim 1 , wherein said concentrated population of adipose-derived regenerative cells further comprises an additive.
29. The method of claim 28 , wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, a growth factor, a tissue or cell re-aggregation inhibitor, and a scaffold, or any combination thereof.
30. The method of claim 7 , wherein said concentrated population of adipose-derived regenerative cells further comprises an additive.
31. The method of claim 30 , wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, a growth factor, a tissue or cell re-aggregation inhibitor, and a scaffold, or any combination thereof.
32. The method of claim 13 , wherein said concentrated population of adipose-derived regenerative cells further comprises an additive.
33. The method of claim 32 , wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, a growth factor, a tissue or cell re-aggregation inhibitor, and a scaffold, or any combination thereof.
34. The method of claim 1 , wherein said step of providing to the subject a composition comprising a concentrated population of adipose-derived regenerative cells improves exercise tolerance in said subject.
35. The method of claim 34 , wherein the subject is human.
36. The method of claim 34 , wherein the concentrated population of adipose-derived regenerative cells comprises precursor cells.
37. The method of claim 34 , wherein the composition is provided to said subject in a bolus.
38. The method of claim 34 , wherein the composition is provided to said subject in multiple doses.
39. The method of claim 34 , wherein the composition is provided to said subject via at least one of an endomyocardial, epimyocardial, intraventricular, intracoronary, retrograde coronary sinus, intra-arterial, intra-pericardial, or intravenous administration route.
40. The method of claim 34 , wherein said concentrated population of adipose-derived regenerative cells is isolated in a closed system.
41. The method of claim 34 , wherein said concentrated population of adipose-derived regenerative cells is not cultured.
42. The method of claim 40 , wherein said concentrated population of adipose-derived regenerative cells is not cultured.
43. The method of claim 34 , wherein said concentrated population of adipose-derived regenerative cells further comprises an additive.
44. The method of claim 43 , wherein said additive is selected from the group consisting of a disaggregation agent, an immunosuppressive agent, a growth factor, a tissue or cell re-aggregation inhibitor, and a scaffold, or any combination thereof.
45. The method of claim 1 , wherein said subject has acute myocardial infarction.
46. The method of claim 1 , wherein said subject has ischemic heart disease.
47. The method of claim 7 , wherein said subject has acute myocardial infarction.
48. The method of claim 7 , wherein said subject has ischemic heart disease.
49. The method of claim 13 , wherein said subject has acute myocardial infarction.
50. The method of claim 13 , wherein said subject has ischemic heart disease.
51. The method of claim 1 , wherein the composition provides a minimum concentration of 5.5×10 4 adipose-derived cells.
52. The method of claim 7 , wherein the composition provides a minimum concentration of 5.5×10 4 adipose-derived cells.
53. The method of claim 13 , wherein the composition provides a minimum concentration of 5.5×10 4 adipose-derived cells.
54. The method of claim 1 , wherein the frequency of stem cells in the concentrated population of adipose-derived regenerative cells is at least 0.1%.
55. The method of claim 7 , wherein the frequency of stem cells in the concentrated population of adipose-derived regenerative cells is at least 0.1%.
56. The method of claim 13 , wherein the frequency of stem cells in the concentrated population of adipose-derived regenerative cells is at least 0.1%.
57. The method of claim 7 , wherein said step of providing to the subject a composition comprising a concentrated population of adipose-derived regenerative cells improves exercise tolerance in said subject.
58. The method of claim 13 , wherein said step of providing to the subject a concentrated composition comprising a population of adipose-derived regenerative cells improves exercise tolerance in said subject.
59. The method of claim 1 , wherein said concentrated population of adipose-derived regenerative cells is cryopreserved.
60. The method of claim 7 , wherein said concentrated population of adipose-derived regenerative cells is cryopreserved.
61. The method of claim 13 , wherein said concentrated population of adipose-derived regenerative cells is cryopreserved.